173 related articles for article (PubMed ID: 21712189)
1. Analysis of pharmacogenetic traits in two distinct South African populations.
Ikediobi O; Aouizerat B; Xiao Y; Gandhi M; Gebhardt S; Warnich L
Hum Genomics; 2011 May; 5(4):265-82. PubMed ID: 21712189
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity.
Dandara C; Lombard Z; Du Plooy I; McLellan T; Norris SA; Ramsay M
Pharmacogenomics; 2011 Dec; 12(12):1663-70. PubMed ID: 22118051
[TBL] [Abstract][Full Text] [Related]
3. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.
Kohlrausch FB; Carracedo Á; Hutz MH
Mol Biol Rep; 2014 Mar; 41(3):1453-60. PubMed ID: 24443221
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
[TBL] [Abstract][Full Text] [Related]
8. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the genetic profile of CYP2C19 in two South African populations.
Drögemöller BI; Wright GE; Niehaus DJ; Koen L; Malan S; Da Silva DM; Hillermann-Rebello R; La Grange AM; Venter M; Warnich L
Pharmacogenomics; 2010 Aug; 11(8):1095-103. PubMed ID: 20712527
[TBL] [Abstract][Full Text] [Related]
10. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.
Mahungu T; Smith C; Turner F; Egan D; Youle M; Johnson M; Khoo S; Back Dj; Owen A
HIV Med; 2009 May; 10(5):310-7. PubMed ID: 19228205
[TBL] [Abstract][Full Text] [Related]
12. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
[TBL] [Abstract][Full Text] [Related]
13. Influence of ethnicity on pharmacogenetic variation in the Ghanaian population.
Yen-Revollo JL; Van Booven DJ; Peters EJ; Hoskins JM; Engen RM; Kannall HD; Ofori-Adjei D; McLeod HL; Marsh S
Pharmacogenomics J; 2009 Dec; 9(6):373-9. PubMed ID: 19546880
[TBL] [Abstract][Full Text] [Related]
14. Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates.
Pimenoff VN; Laval G; Comas D; Palo JU; Gut I; Cann H; Excoffier L; Sajantila A
Pharmacogenet Genomics; 2012 Dec; 22(12):846-57. PubMed ID: 23089684
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
Yoo HD; Cho HY; Lee YB
Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
[TBL] [Abstract][Full Text] [Related]
18. Inter and intra-ethnic differences in the distribution of the molecular variants of TPMT, UGT1A1 and MDR1 genes in the South Indian population.
Umamaheswaran G; Krishna Kumar D; Kayathiri D; Rajan S; Shewade DG; Dkhar SA; Manjunath S; Ushakiran P; Reneega G; Ritushree K; Adithan C
Mol Biol Rep; 2012 May; 39(5):6343-51. PubMed ID: 22318545
[TBL] [Abstract][Full Text] [Related]
19. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
